Skip to main content
. 2021 Apr 23;14:477–485. doi: 10.2147/PGPM.S291723

Table 3.

Pharmacokinetic Parameters According to Sex, Mode of Administration and Polymorphisms in the Fasting Study

Number AUC0-∞/DW(kg*h*ng/mL*mg) Cmax/DW(kg*ng/mL*mg) Tmax(h) t1/2(h) Vd/F(L/kg) CL/F(L/h*kg)
Sex
Female 18 599.43(157.97) 71.67(15.91) 2.48(0.39) 10.53(2.17) 26.68(7.76) 1.77(0.42)
Male 49 581.64(136.65) 71.25(21.45) 2.27(0.39) 11.06(2.05) 29.43(10.58) 1.83(0.51)
Mode of administration
A 34 572.93(146.10) 66.93(17.40) 2.32(0.42) 10.99(2.33) 29.77(11.21) 1.85(0.47)
B 33 600.31(137.81) 75.92(21.68) 2.33(0.38) 10.84(1.83) 27.58(8.42) 1.77(0.51)
CES1.rs2244613.c.1165.33C.A
GG 23 568.17(136.90) 66.94(15.69) 2.39(0.39) 10.88(2.11) 29.50(10.74) 1.87(0.51)
GT 34 588.36(161.85) 73.31(24.22) 2.28(0.43) 10.80(2.11) 28.71(10.44) 1.83(0.53)
TT 10 621.78(55.46) 75.15(9.82) 2.34(0.31) 11.42(2.04) 26.77(5.90) 1.62(0.16)
CES1.rs8192935.c.257.885T.C
AA 41 560.26(138.88) 66.47(17.78) 2.36(0.40) 10.74(2.20) 29.82(11.31) 1.90(0.52)
AG 21 617.22(152.53) 78.08(23.09) 2.29(0.41) 10.97(1.86) 27.11(7.72) 1.72(0.44)
GG 5 671.53(30.54) 83.29(10.44) 2.25(0.32) 12.14(1.94) 26.00(3.38) 1.49(0.06)
ABCB1.rs1045642.c.3435T.C
GG 22 559.60(138.34) 67.37(19.39) 2.31(0.40) 11.42(2.47) 32.08(13.23) 1.92(0.58)
AG 31 612.81(163.77) 76.08(22.75) 2.35(0.39) 10.59(1.72) 26.43(7.02) 1.75(0.50)
AA 14 570.12(76.99) 67.17(11.34) 2.29(0.43) 10.86(2.16) 28.37(8.46) 1.78(0.24)
ABCB1.rs4148738.c.2482.2236G.A
TT 20 557.03(137.21) 65.89(19.38) 2.31(0.41) 11.54(2.49) 32.31(12.40) 1.93(0.58)
CT 31 610.05(166.35) 76.23(22.81) 2.35(0.40) 10.44(1.62) 26.40(8.25) 1.77(0.52)
CC 16 577.37(82.05) 68.75(12.09) 2.30(0.41) 11.07(2.22) 28.60(8.59) 1.76(0.24)
ABCB1.rs2032582.c.2677T.A.G
AA 16 557.37(82.05) 68.75(12.09) 2.30(0.41) 11.07(2.22) 28.60(8.59) 1.76(0.24)
AC/AT 31 610.05(166.35) 76.23(22.81) 2.35(0.40) 10.44(1.62) 26.40(8.25) 1.77(0.52)
CC/CT/TT 20 557.03(137.21) 65.89(19.38) 2.31(0.41) 11.54(2.49) 32.31(12.40) 1.93(0.58)

Notes: Data are shown as mean (SD).